在红色素受体和致病性JAK2信号传递中JAK2激活的分子基础
Bobin George Abraham1, Teemu Haikarainen1,2, Joni Vuorio3
1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Science advances
|March 8, 2024
概括
简氏激酶2 (JAK2) 的体质突变会导致血液恶性瘤. 这项研究揭示了由特定突变激活JAK2的独特分子机制,为向治疗提供了洞察力.
科学领域:
- 分子生物学分子生物学
- 血液学 血液学 血液学
- 生物物理学的生物物理.
背景情况:
- 简氏激酶2 (JAK2) 对于细胞因子受体信号传递至关重要.
- 在JAK2的体质突变与血液性恶性瘤有关,但它们的激活机制仍然不清楚.
研究的目的:
- 通过特定的伪激酶域突变 (V617F,K539L,R683S) 阐明JAK2激活的基础分子机制.
- 研究这些突变对JAK2二分化和活性的结构和功能后果.
主要方法:
- 定量超分辨率显微镜 (qSMLM) 用于可视化EpoR和JAK2二分化.
- 结晶学分析以确定蛋白质结构.
- 激酶活动测定.
- 原子级模拟和人工智能引导的建模.
主要成果:
- 红素受体 (EpoR) 单体在刺激或JAK2突变时分化.
- 对于JAK2 V617F,K539L和R683S突变体,已经确定了明显的伪激酶二元接口和激活机制.
- 突变改变了致病的全长JAK2二分体结构,特别是在FERM-SH2域.
结论:
- 特定的JAK2伪激酶突变通过独特的二分化和自身抑制破坏机制激活激酶.
- 了解这些突变驱动的激活通路对于开发针对JAK2驱动的血液恶性瘤的向疗法至关重要.
更多相关视频
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


